Figure 1From: Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patientsKaplan–Meier curve shows overall survival (OS) for the non-small-cell lung cancer (NSCLC) patients receiving tyrosine kinase inhibitors drugs related to ATP binding cassette superfamily G member 2 (ABCG2) genotypes at 34 G/A (A, p = 0.005), 421 C/A (B, p = 0.823) and 1143 C/T (C, p = 0.872).Back to article page